Zohra Layegh

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 4

Top Topics

Mass Spectrometry

Ulcerative Colitis

Clinical Practice

Top Venues

Therapeutic drug monitoring

International journal of rheumatic diseases

This page only lists publications with an associated author ORCID identifier.

Publications

Dahham Alsoud, Dirk Jan A R Moes, Zhigang Wang, Rani Soenen, Zohra Layegh, Murray L Barclay, Tomoyuki Mizuno, Iris K Minichmayr, Ron J Keizer, Sebastian Georg Wicha, Gerrit J Wolbink, Jo Lydie Wilfried Lambert, Severine Vermeire, Annick de Vries, Konstantinos Papamichael, Núria Padullés-Zamora, Erwin Dreesen
Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic drug monitoring 46 (3) (2024)
Dahham Alsoud, Dirk Jan A R Moes, Zhigang Wang, Rani Soenen, Zohra Layegh, Murray L Barclay, Tomoyuki Mizuno, Iris K Minichmayr, Ron J Keizer, Sebastian Georg Wicha, Gerrit J Wolbink, Jo Lydie Wilfried Lambert, Severine Vermeire, Annick de Vries, Konstantinos Papamichael, Núria Padullés-Zamora, Erwin Dreesen
Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic drug monitoring 46 (3) (2024)
Dahham Alsoud, Dirk Jan A R Moes, Zhigang Wang, Rani Soenen, Zohra Layegh, Murray L Barclay, Tomoyuki Mizuno, Iris K Minichmayr, Ron J Keizer, Sebastian Georg Wicha, Gerrit J Wolbink, Jo Lydie Wilfried Lambert, Severine Vermeire, Annick de Vries, Konstantinos Papamichael, Núria Padullés-Zamora, Erwin Dreesen
Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic drug monitoring (2024)
Zohra Layegh, Jill Ruwaard, Renske C F Hebing, Merel J L' Ami, Wilfred van der Weele, Mike T Nurmohamed, Charlotte Krieckaert, Gertjan Wolbink
Efficacious transition from reference infliximab to biosimilar infliximab in clinical practice. International journal of rheumatic diseases 22 (5) (2019)